Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

CONCLUSIONS: RBs in this patient population were generally safe. Pneumothorax was the most frequent complication; bleeding, while infrequent, increased the risk of severe events. The diagnostic yields and complications of any particular modality should therefore be discussed with prospective clinical trial participants. PMID: 28499641 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28499641?dopt=Abstract

Source: J Formos Med Assoc - May 9, 2017 Category: General Medicine Authors: Liao BC, Bai YY, Lee JH, Lin CC, Lin SY, Lee YF, Ho CC, Shih JY, Chang YC, Yu CJ, Chih-Hsin Yang J, Yang PC Tags: J Formos Med Assoc Source Type: research